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Abstract
Purpose
Early diagnosis and treatment of multiple sclerosis-related progressive multifocal leukoen-
cephalopathy (PML) significantly improve clinical outcomes. However, there is a lack of
information regarding the restart of immunomodulatory therapy in the post-PML setting,
when multiple sclerosis activity reappears. We aimed at the examination of metabolic differ-
ences using 1H-magnetic resonance spectroscopy (1H-MRS) in multiple sclerosis patients
at various post-PML stages and at the exploration of differences according to their disease
and JC virus (JCV) status.
Methods
1H-MRS of PML lesions was carried out on 15 relapsing-remitting multiple sclerosis patients
with natalizumab-associated PML. Patients were grouped according to their stage after
PML infection as early post-PML, less than 19 months after PML onset (n = 5), or late post-
PML group, more than 23 months after PML onset (n = 10). The latter group was further cat-
egorized according to persisting JCV load in the cerebrospinal fluid.
Results
Early post-PML patients showed significantly higher Lipid/Creatine ratios within PML lesions
than late post-PML (p = 0.036). Furthermore, N-Acetyl-Aspartate/Creatine and N-Acetyl-
Aspartate/Choline were significantly reduced in early post-PML and late post-PML lesions
relative to normal-appearing white matter. In late post-PML, virus-positive patients showed
significantly higher ratios of Choline/Creatine (p = 0.019) and consequently a reduced N-
Acetyl- Aspartate/Choline ratio (p = 0.010) in contrast to virus-negative patients. In late post-
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PML patients with persisting viral load, an elevated Choline/Creatine ratio correlated signifi-
cantly with higher disability.
Conclusions
1H-MRS may provide additional information related to underlying PML disease activity in
various post-PML stages. In particular, Choline/Creatine levels, Lipid levels, and N-Acetyl-
Aspartate/Choline are relevant markers in the post-PML setting, taking also the JCV status
into account.
Introduction
Progressive multifocal leukoencephalopathy (PML), an opportunistic infection of the central
nervous system caused by the John Cuningham Virus (JCV) occurs predominantly in
immune-compromised patients. Patients with Human Immunodeficiency Virus (HIV) infec-
tion are principally affected [1], but JCV also occurs as a rare side effect in natalizumab-treated
patients with relapsing-remitting multiple sclerosis (RRMS) [2, 3]. Furthermore, single cases
of PML associated with other disease-modifying therapies (dimethyl fumarate and fingolimod)
treatment have been described [4, 5].
The clinical outcome of natalizumab-associated PML patients with reported survival rates
of 76% to 80% [6] (https://www.biogenidec.com) is much better than in HIV-PML or other
populations, such as transplant recipients [7], and standardized therapy regimes during the
course of immune reconstitution inflammatory syndrome (IRIS) have been recommended [8].
Therapeutic interventions include plasma exchange or immunoadsorption to accelerate the
elimination of the monoclonal antibody of natalizumab and dedicated treatment by corticoste-
roid therapy during IRIS. Additionally, based on expert recommendations only, mefloquine
and mirtazapine were used, both inducing possible inhibitory effects on virus replication,
although precise treatment effects for both drugs remain unclear [3, 9–11]. Longitudinal
observations have shown that in PML survivors functional disability usually stabilizes at
reduced levels after about six months and tends to stay stable beyond 18 months after PML
diagnosis unless new MS relapses occur [6, 8]. However, there is a lack of information regard-
ing the restart of immunomodulatory therapy in the post-PML setting, when MS activity reap-
pears. In a recent study, a restart of immunomodulatory treatment in post-PML was
recommended when new MS disease activity occurs and cerebrospinal fluid (CSF) is proven
JCV-free [8].
Unlike other magnetic resonance (MR) techniques, proton MR spectroscopy (1H-MRS)
offers the opportunity to characterize metabolic changes in pathologic lesions as well as in nor-
mal-appearing brain tissue [12]. To date, only a few case reports describe 1H-MRS findings in
natalizumab-associated PML, bearing no relation to the post-PML setting [13–15]. In HIV-
associated PML typical 1H-MRS findings include reduced N-Acetylasparate (NAA) and
increased Choline (Cho) and Lipid (Lip) levels with especially elevated metabolite ratios of
Cho and Lip to Creatine (Cr) during the IRIS phase [16, 17]. Investigating metabolic changes
in post-PML lesions could be useful to assess ongoing disease activity in this phase of clinical
stabilization and may provide additional information to estimate inflammatory conditions in
the post-PML setting. Thus, the primary goals of this MRS study were the examination of met-
abolic profiles in PML lesions of MS patients in the post-PML setting, and the exploration of
differences according to their JCV status.
1H-magnetic resonance spectroscopy in post-PML lesions
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Material and methods
Patients and treatment
Fifteen RRMS patients were included (9 female, 6 male) between June 2014 and September
2015, who were referred to our clinic for clinical re-evaluation at different stages after a natali-
zumab-associated PML. They received MR imaging and 1H-MRS in the post-PML setting. The
details of the former PML diagnosis and disease course and the functional outcome of the
study population have been reported recently [18] [8, 19]. Summarizing, after the onset of neu-
rological symptoms consistent with PML, the diagnosis was verified by JCV DNA detection in
the CSF in 14 patients, consistent with a diagnostic accuracy of “definitive” according to the
PML consensus statement of the American Association of Neurology (AAN) [20]. In one CSF
JCV-negative patient, the clinical presentation and MRI findings were indicative of PML
(diagnostic accuracy “possible”) and no other differential diagnosis was found [20]. CSF sam-
ples after lumbar puncture were analyzed by PCR for JCV DNA at the Department of Virol-
ogy, University of Du¨sseldorf. In all included patients IRIS, associated with gadolinium
enhancement in PML lesions, was observed. After PML diagnosis all patients received plasma
exchange/immunoadsorption to remove natalizumab and supportive treatment with meflo-
quine and mirtazapine [8].
Clinical disability during the course of disease was extracted from the patient files and mea-
sured by the Expanded Disability Status Scale (EDSS) and Karnofsky Performance Scale (KPS)
[21, 22], one year before the PML diagnosis, at PML diagnosis and, post-PML, six to twelve
months after the PML diagnosis, and at the time of the 1H-MRS examination. The residual
PML-related functional worsening (KPS drop, EDSS rise) was expressed as the EDSS and KPS
difference between scoring one year before PML diagnosis and scoring at the time of MR
acquisition.
The study was approved by the ethics committee of the Ruhr-University Bochum (approval
no. 4566–13) and was conducted according to the principles expressed in the Declaration of
Helsinki. Written informed consent was obtained from all patients.
Proton magnetic resonance spectroscopy (1H-MRS) and MR imaging
1H-MRS and MRI of the brain were performed on a single 3 Tesla MRI System (Philips
Achieva, Best, The Netherlands) using a 32-channel head matrix coil. To localize the PML
lesions and positioning of the volume of interest (VOI) for MRS, isotropic 3D sequences were
performed, consisting of sagittal T1 FFE (TR/TE: 10/4.6ms, TI: 1000ms, ETL 164, matrix
240x240, 180 slices, resolution 1x1x1mm) with and without Gadolinium administration, and
sagittal FLAIR (TR/TE: 4800/291ms, TI: 1650ms, ETL 182, matrix 240x240, 170 slices, resolu-
tion 1x1x1mm). For MRS, a 2D-PRESS chemical shift imaging sequence (TR/TE: 2000/45 ms,
bandwidth 2000 Hz, 1024 spectral points, 128 measurements) covering an axial field of view
(230x190x15 mm; resolution 10x10x15 mm) was used.
The VOI (82x90x15 mm) was positioned apart from air-tissue interfaces and surround-
ing bones and fat, aiming to cover the PML lesions and normal appearing white matter
(NAWM) If possible, single MS lesions in white matter regions which were apparently not
affected by PML were also covered. The inserted axial FLAIR images in Fig 1 illustrate
typical positioning of the VOI covering PML lesions as well as NAWM. Outer volume sup-
pression by circular saturation slices was used. The preparation phase of MRS included
automatic procedures for water suppression, shimming, and tuning of the radiofrequency
and gradient system and an acquisition without water suppression for correction of mag-
netic field distortions.
1H-magnetic resonance spectroscopy in post-PML lesions
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Identification of the PML lesion and differentiation from MS lesions was performed by visi-
ble comparison of pre-existing external MRI investigations before the onset of PML in each
patient by an experienced rater (RS, CL). Lesion location, lesion morphology, and (if DWI
images were availyble) diffusion restriction was used to differentiate PML lesions from MS
lesions.
An MRI sum score was obtained at the time of MRS to semi-quantitatively describe the
extension of the PML lesions depending on the affected brain regions of FLAIR-weighted
imaging (range 1–9, from focal lesions affecting one gyrus to bi-hemispheric lesions covering
both hemispheres).
Spectral processing
MRS signals were post-processed using the vendor’s automatic software SpectroView (Philips,
Best, The Netherlands) implemented on an external workstation [23, 24]. The automatic
Fig 1. Exemplary 1H-spectra (2D-PRESS, TR/TE: 2000 / 45 ms). (A) PML lesion early post-PML (E-pPML, male, aged 62 years, 8 months
post-PML); (B) PML lesion late post-PML (L-pPML, female, aged 38 years, 27 months post-PML); (C) NAWM (same patient as (A)); (D) MS
lesion (same patient as (B)). The location of the spectra is marked by yellow squares on the inserted axial FLAIR images.
https://doi.org/10.1371/journal.pone.0176415.g001
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processing included time domain filtering (Gaussian multiplication: 5Hz and exponential mul-
tiplication: -3Hz), residual water suppression by high-pass filtering (width 30 Hz), and fast
Fourier transformation. SpectroView quantifies the frequency domain data by phase correc-
tion and fitting of peaks by using prior knowledge of the expected metabolites. The baseline is
fitted with a polynomial function and subtracted from the whole spectrum.
Metabolite ratios were calculated based on the peak integrals of N-Acetylaspartate (NAA,
2.01 ppm), Creatine (Cr and Cr2, 3.03 and 3.93 ppm), Choline (Cho, 3.23 ppm), and the
summed peak areas of myo-Inositol (mI, 3.58 and 3.64 ppm) and Lipid (Lip, 0.9 and 1.4 ppm).
For each patient, the spectral analysis included metabolite ratios extracted in the center of the
PML lesions, in contralateral NAWM, and in non-PML MS lesions, if present.
Statistical analysis
All statistical analyses were performed using SPSS 22 (IBM SPSS, Chicago, USA). Group dif-
ferences between patient subgroups were explored by Mann-Whitney-U tests for EDSS, KPS,
and metabolite ratios. Group differences regarding age and disease duration were assessed
using Student’s t-test. Differences between the numbers of patients with JCV DNA elimination
and initiation of an immune-modulatory therapy at the time of MRS were explored by Pear-
son’s chi-square tests. Because of the explorative character of the study and small group sizes,
correction for multiple comparisons was omitted. Associations between MRS results and clini-
cal parameters including the EDSS and KPS as well as JCV load and PML lesion extension
score were conducted using Spearman correlation analyses.
Results
Patients: Clinical status and grouping according to JCV status and post-
PML time
The patients’ demography and clinical status are summarized in Table 1; details are supplied
in S1 Table. At the time of 1H-MRS (8 months to 67 months after PML diagnosis according to
the AAN criteria) 11 patients (73%) had successfully eliminated the JCV, while in four patients
Table 1. Demography and clinical status of 15 RRMS patients in the post-PML phase.
early post-PML
(E-pPML)
late post-PML
(L-pPML)
p-value late post-PML
JCV-
late post-PML
JCV+
p-value
PML disease duration at MRS months) median [range] 12 [8–19] 38 [23–67] 0.001 38 [23–67] 40 [26–56] 0.914
n 5 10 6 4
female no.,(%) 2 (40%) 7 (70%) 7 (70%) 2 (40%)
age (years) mean±SD 39±16 40 ±5 0.761a 41 ±6 38±4 0.407a
MS disease duration until PML diagnosis (years) mean±SD 12.8±8.9 12.3±4.2 0.909a 11.7±4.4 11.0±4.8 0.826a
EDSS change (1y before PML—time of MR) median [range] -1.5 [0;-4.5] -3.0 [-1.5;-6.5] 0.254b -2.5 [0;-4.5] -4.0 [-2;-6.5] 0.171b
KPS change (1y before PML—time of MR) median [range] -10 [0; -30] -20 [-10; -60] 0.165b -15 [0; -40] -40 [-20; -60] 0.038b
JCV elimination at time of MR no.(%) 5 (100%) 6 (60%) 0.099c 6 (100%) 0 (0%) 0.002c
IMT post-PML at time of MR no.(%) 2 (40%) 6 (60%) 0.464c 4 (67%) 2 (50%) 0.598c
SD: standard deviation; IMT: immunomodulatory therapy; KPS: Karnofsky performance scale, EDSS: extended disability status scale JCV+, JCV-: JCV
DNA in CSF positive/negative; RRMS: relapsing-remitting multiple sclerosis;
p-values: significance of group differences;
a: t-tests;
b: Mann-Whitney-U-tests;
c: Pearson’s chi-square tests.
https://doi.org/10.1371/journal.pone.0176415.t001
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(time after PML diagnosis: 40.5±15.2 months [mean±standard deviation (SD)]) the CSF exam-
inations remained JCV-positive. To compare those patients who had a longstanding (more
than 23 months) persistent JCV-positive status (late post-PML JCV+) with matched JCV-neg-
ative patients (JCV-), we classified the JCV patients according to the time interval between the
PML diagnosis and the MR date (disease duration at MRS). Thus, we formed a late post-PML
group (L-pPML; n = 10 patients; time after PML diagnosis: 38.0 [23.0–67.0] months [median,
range]) and an early post-PML group (E-pPML; n = 5 patients; time after PML diagnosis: 12.0
[8.0–19.0] months [median, range]). Using this stratification, there were no significant differ-
ences in the distribution of the disease duration at MRS between the L-pPML and the late
post-PML JCV+ groups (p = 0.914). In contrast, there was no significant overlap between the
distributions of the E-pPML and L-pPML groups (p = 0.001). Therefore, this classification was
also used to inspect group differences according to the disease duration at MRS examination
between the early and late pPML group.
When comparing E-pMPL and L-pPML patients (Table 1), there were no statistically signif-
icant differences regarding age, disease duration before the onset of PML, and change of EDSS
and Karnofsky-performance scale between PML diagnosis and time of MRS (Table 1). When
subdividing L-pPML patients according to their JCV status, a significantly more severe KPS
drop was found in late post-PML JCV+ patients, indicating more persistent disability in this
group as compared to JCV-negative post-PML patients (late post-PML JCV-, see Table 1).
In the E-pPML group, an immunomodulatory treatment (IMT) was re-initiated in two
patients (40%) by using dimethyl fumarate and interferon beta-1a before the MR examination.
In all JCV- patients of the L-pPML group an immunomodulatory treatment (dimethyl fuma-
rate, fingolimod, interferon beta-1a, glatiramer acetat) was restarted before the MR examina-
tion. In two of these patients (33%) the IMT was interrupted at the time of MR examination.
In two patients of the JCV+ group, IMT had not yet been initialized at the time of MRS. One
was free of IMT at MR examination after a transient period of glatiramer acetat treatment, and
the other patient was treated with intravenous immunoglobulin at the time of MRS (IMT ini-
tialization with interferon beta-1a, later replaced by dimethyl fumarate). There were no signifi-
cant differences either between the fractions of treated and untreated patients or between the
JCV+ and JCV-, or E-pPML and L-pPML groups (Table 1).
The overall survival rate of this study population was 100% [18, 19].
1H-MRS findings
Fig 1 illustrates typical MRS spectra found in PML lesions (Fig 1A: E-pPML, 8 months post
PML diagnosis, and Fig 1B: L-pPML, 27 months post PML diagnosis); NAWM (Fig 1C, same
patient as in A); and a MS lesion which was apparently not affected by the PML (Fig 1D, same
patient as in B). It depicts elevated levels of free lipid signal in the PML lesion of the E-pPML
patient and, to a lesser extent, in the L-pPML patient when compared to the NAWM spectrum
in Fig 1C. The NAWM spectrum and the spectrum of the MS lesions of the PML patients
depicted in Fig 1 showed typical metabolic patterns reported for healthy brain white matter
(staircase-like proportion of the peak heights of Cho, Cr, and NAA) and MS lesions (relative
reduction of NAA/Cr and possible increase of Cho/Cr) with similarly low lipid levels in both
spectra [25] For comparison, representative MRS spectra of normal supratentorial white mat-
ter of a representative healthy control and of a white matter MS lesion of a RRMS patient with-
out PML are provided as supplementary material (S1 Fig) [25].
Quantitative MRS analysis results are given in Table 2. Since no statistically significant dif-
ferences between the post-PML subgroups were detected in the spectral results of MS lesions
and NAWM, the spectral results of MS lesions (n = 5) and of NAWM (n = 14) were pooled
1H-magnetic resonance spectroscopy in post-PML lesions
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into single groups. Comparing metabolite ratios of NAA, Cho, and Lip to Cr as well as the
NAA/Cho ratio between the spectra acquired in PML lesions in the E-pPML and L-pPML
group and the NAWM results, there was a significantly elevated Lip/Cr ratio in E-pPML com-
pared to L-pPML (p = 0.036) and to NAWM (p = 0.008). Furthermore, the levels of NAA/Cr
and NAA/Cho were significantly reduced in E-pPML (p = 0.044/ p = 0.044) and in L-pPML
(p = 0.002/ p = 0.006) lesions relative to NAWM. Because of the marked fraction of patients
who could not eliminate JCV in the CSF in the L-pPML group (40%; 4/10 patients), we com-
pared the metabolite ratios between JCV-positive (n = 4) and JCV-negative (n = 6) patients.
We observed a significantly different Cho/Cr ratio (p = 0.019) in the sense of higher Cho/Cr in
the JCV-positive group and a consequently reduced NAA/Cho ratio in JCV-positive patients
compared to JCV-negative patients (p = 0.010), probably reflecting different Choline levels.
Furthermore, the Lip/Cr ratio was significantly increased in the MS lesions of PML patients
compared to NAWM (p = 0.034).
Correlation analysis of 1H-MRS metabolites and EDSS/ KPS
A significant positive correlation between the Cho/Cr ratio and KPS change was found in L-
pPML patients (Fig 2, Spearman correlation rho = -0.566, p = 0.044), relating more severe
residual PML-related functional worsening to higher Cho/Cr levels in the PML lesions of late
post-PML patients. There was no further significant association between any 1H-MRS
Table 2. Spectroscopy results. Metabolite ratios in subgroups of PML lesions, MS lesions, and NAWM.
metabolite ratio
median [range]
early post-PML
(E-pPML)
n = 5
late post-PML
(L-pPML)
n = 10
late post-PML
JCV -
n = 6
late post-PML
JCV+
n = 4
all NAWM
n = 14
all MS
n = 5
NAA/Cr 1.07
[0.88,1.74]
ap = 0.044
bp = 0.095
1.26
[0.92,1.44]
ap = 0.002
bp = 0.040
cp = 0.513
1.28
[1.02,1.44]
dp = 0.171
cp = 0.329
1.03
[0.92,1.29]
1.52
[1.21,1.88]
1.58
[1.21,2.13]
ap = 0.500
Cho/Cr 0.80
[0.66,1.26]
ap = 0.500
bp = 0.690
0.85
[0.66,1.21]
ap = 0.108
bp = 0.953
cp = 0.440
0.74
[0.65,0.85]
dp = 0.019
cp = 0.247
0.99
[0.85,1.21]
0.76
[0.45,1.04]
0.81
[0.67,1.33]
ap = 0.219
Lip /Cr 1.14
[0.6,1.77]
ap = 0.008
bp = 0.413
0.36
[0.12,0.97]
ap = 0.403
bp = 0.099
cp = 0.036
0.52
[0.12,0.97]
dp = 0.730
cp = 0.095
0.28
[0.22,0.44]
0.45
[0.28,1.06]
0.70
[0.48,1.65]
ap = 0.034
NAA/Cho 1.52
[0.85,2.51]
ap = 0.044
bp = 0.421
1.5
[0.87,1.96]
ap = 0.006
bp = 0.254
cp = 0.954
1.73
[1.52,1.96]
dp = 0.010
cp = 0.177
0.99
[0.87,1.49]
2.14
[1.3,3.23]
1.73
[1.02,2.45]
ap = 0.391
JCV+, JCV-: JCV DNA in CSF positive/negative;
p-values: significance of group differences by Mann-Whitney-U tests:
a
= compared to NAWM;
b
= compared to MS lesions;
c
= compared to E-pPML;
d
= comparison JCV+ vs. JCV-
bold: significant with p<0.050
https://doi.org/10.1371/journal.pone.0176415.t002
1H-magnetic resonance spectroscopy in post-PML lesions
PLOS ONE | https://doi.org/10.1371/journal.pone.0176415 April 26, 2017 7 / 13
metabolite ratio and clinical parameters such as the EDSS, the KPS, the PML lesion extension
score at MRS, or the JCV load at PML diagnosis in any of the patient groups.
Discussion
Results of the current 1H-MRS study indicate different MRS patterns of metabolite profile
changes in the post-PML setting of MS patients. The spectra of PML lesions compared to the
spectra of NAWM in patients in the E-pPML phase were dominated by marked lipid peaks
and reduced NAA levels, reflected by elevated Lip/Cr and low values of NAA/Cr and NAA/
Cho.
By contrast, metabolic profiles in PML lesions of L-pPML patients showed normal Lip/Cr
levels while low NAA/Cr and NAA/Cho persisted compared to spectra obtained in NAWM.
NAA, an amino-acid derivate exclusively synthesized in neurons, which is distributed along
the anterograde axonal transport, is usually interpreted as a marker of neuronal viability, espe-
cially for axonal integrity in the white matter [12, 26], while increased Cr has been ascribed to
gliosis [27]. As previously described in HIV-related PML patients and in a case report of a sin-
gle MS patient with natalizumab-associated PML, the decreased NAA/Cr ratio returned to
baseline during the course of PML-IRIS, suggesting that neuronal dysfunction may in part be
reversible [17, 28]. Our study indicates that similar dynamic changes exist in natalizumab-
associated PML patients. In the PML lesions of E-pPML as well as in L-pPML NAA/Cr was
reduced, probably due to partially persistent axonal integrity loss. This was also reflected by
the accordant reduced NAA/Cho ratio in both groups of post-PML patients.
Fig 2. Association between Cho/Cr (in PML lesions) and the PML-related change in KPS in late post-
PML patients (L-pPML). The KPS change was calculated as the difference between the time points: one
year before PML diagnosis and the time of the MRS examination. The dotted line depicts a linear regression.
https://doi.org/10.1371/journal.pone.0176415.g002
1H-magnetic resonance spectroscopy in post-PML lesions
PLOS ONE | https://doi.org/10.1371/journal.pone.0176415 April 26, 2017 8 / 13
The most relevant metabolite in PML lesions of post-PML patients seems to be the marked
elevated lipid peak (Lip/Cr) in E-pPML patients, which returned to normal levels in L-pPML.
Lipid resonances are interpreted as primary markers of cell membrane breakdown [29] and
are linked to the presence of immune cells, including T cells in vitro [30, 31]. Therefore, high
MRS lipid signals are interpreted as markers of activated lymphocytes [32]. In HIV-related
PML lesions, increased Lip/Cr ratios were regarded as a result of the infiltration of activated T
cells in the PML lesions [17]. Applying this information to post-PML MS-patients, our results
suggest that elevated lipid levels may indicate an ongoing inflammatory process, which is
regressive in the later post-PML phase. Correspondingly, the lipid peak might serve as a surro-
gate marker for persisting inflammation within PML lesions.
Another important finding of our study is related to the JCV status of PML patients in the
later stage. We explored spectroscopic differences in PML lesions between patients who had
eliminated the JCV and patients with persisting JCV load in the L-pPML group. Specifically,
patients with persisting JCV load in the CSF showed increased Cho/Cr levels and a respectively
decreased NAA/Cho ratio compared to patients with negative JCV load in the CSF. The Cho-
line peak is determined by several Cho-containing phospholipids of cell membranes, in this
regard predominantly of myelin. Regarding neuroinflammatory diseases, elevated MRS Cho-
line levels represent abnormal Choline mobility, in turn suggesting demyelination or remyeli-
nation and inflammation [12, 33]. In PML the grade of increased Cho/Cr levels may reflect
ongoing disease activity, which in terms of JCV persistence may indicate continuous inflam-
matory processes aiming at the complete elimination of the virus. Despite the explorative char-
acter of this study with small patient subgroups, these findings indicate that increased Cho/Cr
may be related to inflammatory activity. In accordance with the hypothesis that elevated Cho/
Cr ratios may represent ongoing inflammation, a significant correlation between Cho/Cr and
worsening of clinical performance during the PML (KPS change between the MRS time and a
year before PML diagnosis) could be shown in L-pPML, suggesting that these MRS findings
are clinically relevant.
In addition, the 2D-spectroscopic technique allowed us to investigate a few focal MS
lesions. In these non-PML MS lesions we found slightly elevated Lip/Cr levels compared to
NAWM without other PML-like spectral changes. Given the sparse nature of MRS studies,
there is a lack of comparable MRS findings in pure MS lesions of PML patients. Sinnecker
et al. demonstrated moderately decreased levels of NAA in an exemplary MS lesion in a case
study of one PML patient [15]. Even though free lipid signal has previously been reported in
localized active MS lesions [34], in the MS lesions of patients with prior PML a widespread
affection of brain white matter by inflammatory processes, extending beyond the visual loca-
tion of PML lesions, has to be taken into consideration as an alternative source of lipid eleva-
tion. The major metabolite ratios (NAA/Cr, NAA/Cho, Cho/Cr) in MS lesions did not
significantly differ from NAWM, which was in accordance with a recent larger MRS study in
which a high similarity in the individual spectra of chronic MS lesions and contralateral
NAWM was described [35]. These results, however, should be interpreted with caution, due to
the low number of MS lesions studied. Given the herein used 2D MRS technique, we cannot
fully exclude that data from MS white-matter lesions were ‘contaminated’ by volume averaging
from adjacent NAWM, CSF, or nearby gray matter.
A few more limitations of our study have to be acknowledged. Firstly, the statistical power
of the analysis was limited due to small patient subgroups in this exploratory study. Neverthe-
less, given that larger MRS studies in natalizumab-associated PML cases are lacking, our results
are, in part, in line with previous MRS findings in HIV-related PML patients, suggesting simi-
lar metabolic profile changes in the course of PML [17].
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Secondly, we compared independent groups of RRMS patients who were in early and late
disease states after PML to draw conclusions about 1H-MRS metabolite changes over time.
This exploratory cross-sectional approach seems appropriate for a pilot study; however, future
longitudinal studies with larger groups of MS patients with natalizumab-associated PML are
required in order to evaluate the temporal changes of metabolic patterns in the post-PML set-
ting. Furthermore, additional information about spectroscopy findings in the course of early
PML and PML-IRIS are required.
In post-PML patients, especially in non-eliminators of the JCV, the restart of immunomod-
ulatory therapy when MS activity reappears is a difficult and precarious decision. Admittedly
there is a non-evidence based recommendation to restart IMT when the CSF is proven JCV-
free; nonetheless, in cases of early reappearing MS activity and occurring relapses, therapeutic
intervention can become necessary [8]. Different exemplary proposals regarding post-PML
MS therapy exist, which points to the fragile immunological situation in post-PML RRMS
patients [36]. The present exploratory study including a relatively small number of PML
patients indicated that 1H-MRS of PML lesions, especially regarding Cho/Cr levels in JCV-
positive post-PML patients, as well as lipid levels and NAA/Cho in the post-PML period, can
provide additional and potentially clinically relevant information related to ongoing PML dis-
ease activity. In the future, additional longitudinal MRS studies including higher numbers of
PML patients are required to investigate the clinical relevance of MRS results in the course of
the disease. Potentially, 1H-MRS might contribute to the evaluation of the inflammatory situa-
tion of MS patients in the post-PML setting when re-initiation the immunomodulatory ther-
apy is being discussed.
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